InvestSMART

Sonic Healthcare Limited (ASX:SHL)

ALERT: Price-sensitive ASX Announcement for SHL
Current share price for SHL : $21.880 -6.86 (-23.87%)+
Announcement
Release
21 Aug 2025 9:04AM
Price at Release
$28.740
Full Release
download
Summary
Sonic Healthcare Limited reported a net profit of A$514 million for the financial year ending 30 June 2025, with revenues totaling approximately A$9.6 billion, reflecting an 8% revenue growth and a 7% increase in net profit compared to the previous year. The company achieved 5% organic revenue growth and expanded its EBITDA margin by 40 basis points on a normalised basis. Major growth drivers included the completion of the LADR Laboratory Group acquisition in Germany, the acquisition of Cairo Diagnostics in the USA, and the successful integration of the Hertfordshire and West Essex NHS outsource contract in the UK. The company is also expecting strong earnings growth in FY2026, driven by synergies from acquisitions and US initiatives, with anticipated EPS growth of up to 19%. Sonic's progressive dividend policy was maintained, marking a slight increase to a final dividend of 63 cents.
Key Points
  • Reported net profit of A$514 million for FY2025.
  • Revenues totaled approximately A$9.6 billion.
  • Achieved 5% organic revenue growth.
  • Expanded EBITDA margin by 40 basis points.
  • Completed the LADR Laboratory Group acquisition in Germany.
  • Acquired Cairo Diagnostics in the USA.
  • Integrated the Hertfordshire and West Essex NHS contract in the UK.
  • Expecting strong earnings growth and up to 19% EPS growth in FY2026.
  • Maintained a progressive dividend policy with a slight increase.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.